Bavarian Nordic Receives $1.6-Billion Contract from HHS - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bavarian Nordic Receives $1.6-Billion Contract from HHS


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Kvistgård, Denmark (June 4)—Bavarian Nordic received a $1.6-billion contract from the US Department of Health and Human Services (HHS, Washington, DC) to manufacture and deliver 20 million doses of its smallpox vaccine “Imvamune.”

HHS is supplying a base contract payment of $500 million to support additional research and development of Imvamune for the vaccine’s potential use during an emergency. The payment also will fund nonclinical and clinical studies for the vaccine.

The contract includes advance and milestone payments worth as much as $150 million and contractual options worth $1.1 billion. The contractual-options payment would fund further clinical studies of the vaccine that extend the license to include those infected with HIV, children, and the elderly. The payment also could be used to procure up to 60 million additional doses of Imvamune.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here